(Source: Business Wire)Merge Healthcare, (NASDAQ: MRGE), a leading health IT solutions provider, today announced the addition of three Biotronics3D applications to its eFilm eCommerce channel: Diagnostic 3D, Vessel Review and Colon Review. Each module brings fast access to an array of advanced visualization tools that assist in non-invasive viewing and diagnosing of medical conditions. All three modules are currently available via a free trial software download from the Merge Web site.

"Collaborating with Merge Healthcare allows us to introduce these powerful applications to the global eFilm Workstation community, which we believe is a market that values robust, cost-effective and user-friendly applications," says Harry Hatzakis, CEO of Biotronics3D. "Just as these applications will benefit the clinician and the patient, this joint effort brings health care decision makers worldwide access to the latest diagnostic and analytic tools."

"The availability of these advanced applications through the eFilm Web site is certain to ensure new growth of eFilm's global customer base and strengthen our position within certain specialty markets," adds Nancy Koenig, President of Merge's Fusion business unit. "We expect that the free trial period, the choice of annual or perpetual licenses, and the training and support eFilm provides will be well received. We look forward to offering additional Biotronics3D applications as they become available."

The Biotronics3D modules, available at www.merge.com/efilm, can be deployed enterprise-wide through a simple software download, and without the need for specialized hardware or bandwidth capabilities. Each visualization module includes a unique core design with enhanced memory, and uses advanced algorithms and histograms to analyze regions of interest. Other features include intuitive analysis tools and a customizable user interface for optimal user efficiency.

Merge Healthcare develops solutions that automate healthcare data and diagnostic workflow to enable a better electronic record of the patient experience, and to enhance product development for health IT, device and pharmaceutical companies. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years. Additional information can be found at www.merge.com.

Biotronics3D, headquartered in London, England, develops and markets innovative software applications for the diagnostic imaging industry. We provide cutting edge software technologies to improve healthcare by better extracting diagnostic data and transforming it into usable information available at the point-of-care. Biotronics3D Ltd is an EN ISO 13485:2003 certified company. Our flagship product, 3Dnet Suite, has received FDA 510K market clearance and it is CE marked www.biotronics3D.com.

The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words "will," "believes," "intends," "anticipates," "expects" and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.

A service of YellowBrix, Inc.